These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38290907)

  • 41. Comparison of societal guidance on perioperative management of glucagon-like peptide-1 receptor agonists: implications for clinical practice and future investigations.
    Chang MG; Bittner EA
    Can J Anaesth; 2024 Sep; 71(9):1302-1315. PubMed ID: 39187641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound.
    Willson CM; Patel L; Middleton P; Desai M
    Cureus; 2024 Apr; 16(4):e58042. PubMed ID: 38738030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
    Asmar M; Bache M; Knop FK; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2367-75. PubMed ID: 20194711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
    Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.
    Herzlinger S; Horton ES
    Diabetes Res Clin Pract; 2013 Apr; 100(1):1-10. PubMed ID: 23332049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The rationale for combining GLP-1 receptor agonists with basal insulin.
    Cohen ND; Audehm R; Pretorius E; Kaye J; Chapman LH; Colagiuri S
    Med J Aust; 2013 Aug; 199(4):246-9. PubMed ID: 23984780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like peptide 1 based therapy for type 2 diabetes.
    Yu BS; Wang AR
    World J Pediatr; 2008 Feb; 4(1):8-13. PubMed ID: 18402245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
    Spezani R; Mandarim-de-Lacerda CA
    Life Sci; 2022 Jan; 288():120188. PubMed ID: 34861287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
    Klein SR; Hobai IA
    Can J Anaesth; 2023 Aug; 70(8):1394-1396. PubMed ID: 36977934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
    Fineman MS; Cirincione BB; Maggs D; Diamant M
    Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.